RESUMO
Results are submitted of study of the effectiveness of inclusion into the treatment program for patients with chronic lymphoid leukemia of specific (thymalin) and unspecific (plasmapheresis) means and modes of immune correction, which made for more rapid attaining clinical and hematological compensation by comparison with chemotherapeutic agents only. Furthermore, the method of combined use of drugs, attempted for the first time, permitted the functional activity of the lymphoid system to be improved, with the clinical and hematological compensation being achieved in a shorter space of time.
Assuntos
Adjuvantes Imunológicos/uso terapêutico , Leucemia Linfocítica Crônica de Células B/terapia , Plasmaferese , Hormônios do Timo/uso terapêutico , Idoso , Formação de Anticorpos/efeitos dos fármacos , Antineoplásicos Alquilantes/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Clorambucila/administração & dosagem , Terapia Combinada , Ciclofosfamida/administração & dosagem , Feminino , Humanos , Imunidade Celular/efeitos dos fármacos , Masculino , Pessoa de Meia-IdadeRESUMO
Extracorporeal detoxication techniques (hemosorption, plasmapheresis and plasma exchange) were used in a complex therapy of 55 patients with hemolytic disorders of different etiology. The results of clinical and laboratory studies confirm the efficacy of plasmapheresis. Skin surfaces and mucosa became less icteric, the size of the spleen and liver diminished, the levels of free hemoglobin, bilirubin and circulating immune complexes decreased, blood toxicity reduced. Unlike hemosorption, plasmapheresis and plasma exchange had no unfavourable effects on blood cells.